Novelos enrolls first patient in phase 2 ovarian cancer trial

By Elaine Rigoli

Tampa, Fla., July 18 - Novelos Therapeutics, Inc. announced that Dana-Farber/Partners Cancer Care has enrolled the first patient in a phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients.

The company said the primary objective of this open-label, single-arm phase 2 trial is to determine the tumor response rate in a cohort of women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin.

Up to 25 women will be enrolled in the trial and may receive up to six cycles of NOV-002 and carboplatin. Interim results are expected in early 2007.

Novelos, a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, is located in Newton, Mass.

Dana-Farber/Partners is a joint venture non-profit consortium established by Massachusetts General Hospital, The Brigham and Women's Hospital, Inc. and Dana-Farber Cancer Institute.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.